3 widely used medicines classified as carcinogenic by WHO research agency

1. At a Glance

• IARC (International Agency for Research on Cancer), WHO's specialised cancer research agency (headquartered Lyon, France), classified hydrochlorothiazide, voriconazole, and tacrolimus as "carcinogenic to humans" (Group 1) [1][2].
• All three are on the WHO Model List of Essential Medicines and prescribed to millions globally — relevant for GS-III (health policy) and GS-II (WHO/international organisations) [2][3].
• The classification is a hazard identification, not a risk-magnitude verdict; experts caution against discontinuing treatment without medical advice [3].
• Tests IARC's Group 1–4 carcinogen classification system, frequently confused with risk level by aspirants.

2. Why in the News

• IARC published its full evaluation as Volume 137 of the IARC Monographs (2025/2026), following a Working Group of 22 scientists from 14 countries who met at IARC, Lyon, in November 2024 [1][2].
• Findings expand on conclusions first released in The Lancet Oncology, November 2024 [1][3].
• Reported in Indian press (The Hindu, 5 August 2026) as three widely prescribed drugs — for hypertension, fungal infections, and transplant-rejection prevention — being reclassified [3].

3. Background & Evolution

• IARC Monographs Programme evaluates chemical, physical, and biological agents for carcinogenicity, sorting them into Group 1 (carcinogenic), 2A (probably), 2B (possibly), 3 (not classifiable) — a scheme used since the 1970s.
• November 2024: IARC Working Group meets; preliminary findings published in The Lancet Oncology [1].
• 2025/26: Full peer-reviewed monograph released as Volume 137, comprising three separate agent-specific monographs (hydrochlorothiazide, voriconazole, tacrolimus) [1][2].
• August 2026: Findings receive wider Indian media coverage [3].

4. Core Static Facts

Medicine	Use	Cancer Linked	Classification
Hydrochlorothiazide	Thiazide diuretic for hypertension	Squamous cell skin carcinoma, lip cancer, basal cell carcinoma, melanoma, Merkel cell carcinoma, malignant adnexal skin tumours; liver tumours (male mice), pheochromocytoma (female rats)	Group 1 [1][3]
Voriconazole	Broad-spectrum triazole antifungal (invasive aspergillosis, esp. transplant patients)	Squamous cell skin carcinoma (phototoxic mechanism, prolonged therapy in transplant recipients)	Group 1 [1][2][3]
Tacrolimus	Immunosuppressant (organ transplant rejection, graft-versus-host disease prevention)	Non-Hodgkin lymphoma, post-transplant lymphoproliferative disorder; limited evidence for leukaemia, skin carcinoma	Group 1 [1][2][3]

• Publishing body: IARC, WHO's specialised cancer agency, Lyon, France [1].
• Document: IARC Monographs, Volume 137 [1][2].
• All three drugs feature on the WHO Model List of Essential Medicines [2].

5. Multi-Dimensional Analysis

Scientific/Technological

• Evidence graded by IARC's standard hierarchy: "sufficient evidence in humans" + "sufficient evidence in experimental animals" for hydrochlorothiazide [1].
• Voriconazole's carcinogenicity operates via a phototoxic mechanism in patients on prolonged therapy [3].

Social

• Dermatologists flag disproportionate risk in rural, Northeast, hilly, and coastal populations with higher sun exposure — an equity/geography dimension for hydrochlorothiazide users [3].
• Millions of patients globally rely on these essential medicines, raising communication challenges for public health systems.

Ethical/Governance

• Reclassification poses a risk-communication dilemma: hazard identification (can it cause cancer, in principle) vs. risk assessment (how likely, at what dose) — mismanagement could cause a treatment-discontinuation panic.
• Underscores WHO/IARC's precautionary, evidence-review-based institutional mandate independent of national health regulators.

Administrative

• National regulators (e.g., India's CDSCO) and prescribing physicians must decide on updated labelling/monitoring guidance following an international hazard reclassification — a federal/regulatory follow-through gap worth tracking.

6. Recent Developments (last 12-18 months)

• November 2024: IARC Working Group evaluation finalised in Lyon; preliminary results published in The Lancet Oncology [1].
• 2025/2026: Full IARC Monographs Volume 137 released online, detailing evidence for all three agents [1][2].
• 5 August 2026: Indian media (The Hindu) reports the classification, quoting dermatologist Dr Kabir Sardana (ABVIMS/Dr RML Hospital) on regional skin-cancer risk in hydrochlorothiazide users [3].

7. Prelims Hooks

• IARC = International Agency for Research on Cancer, WHO's specialised cancer research agency, based in Lyon, France.
• Three medicines reclassified: hydrochlorothiazide (hypertension), voriconazole (antifungal), tacrolimus (immunosuppressant/anti-transplant-rejection) [3].
• All three placed in IARC Group 1 — "carcinogenic to humans" [1][3].
• Findings published as IARC Monographs, Volume 137 [1][2].
• Preliminary results first appeared in The Lancet Oncology, November 2024 [1].
• Evaluating Working Group comprised 22 scientists from 14 countries [1].
• All three drugs are listed on the WHO Model List of Essential Medicines [2].
• Hydrochlorothiazide linked to squamous cell skin carcinoma, lip cancer, basal cell carcinoma, melanoma, Merkel cell carcinoma [1][3].
• Voriconazole's skin-cancer risk arises via a phototoxic mechanism in transplant patients on prolonged therapy [3].
• Tacrolimus linked to non-Hodgkin lymphoma and post-transplant lymphoproliferative disorder [3].
• IARC's classification system ranges from Group 1 (carcinogenic) to Group 3 (not classifiable).
• Classification is a hazard identification, not advice to stop medication [3].
• Article/report location: quoted expert Dr Kabir Sardana is Director-Professor & HOD, Dermatology, Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Manohar Lohia Hospital, New Delhi [3].

8. Mains Relevance

• GS-II: International institutions and agreements involving India (WHO/IARC), health governance.
• GS-III: Science & technology developments, issues relating to health.
• Possible question stems:
• Discuss the distinction between 'hazard identification' and 'risk assessment' in IARC's carcinogen classification, and its implications for public health communication in India. (GS-III)
• Examine the challenges India's drug regulatory framework faces in responding to international carcinogenicity reclassifications of essential medicines. (GS-II/III)
• What role does the WHO's International Agency for Research on Cancer play in shaping global public health policy? Discuss with reference to recent drug reclassifications. (GS-II)

9. Related Topics to Study Next

• WHO Model List of Essential Medicines — parent framework listing all three drugs; tests drug-access policy linkage.
• CDSCO (Central Drugs Standard Control Organisation) — India's domestic regulator that would respond to such findings.
• IARC Group 1 carcinogens list (e.g., tobacco, asbestos, processed meat) — comparative classification examples.
• National Cancer Registry Programme (ICMR) — India's cancer data-tracking mechanism, relevant to burden assessment.
• Ayushman Bharat / health insurance schemes — policy angle on treatment cost/access if drug substitutes are needed.
• Pharmacovigilance Programme of India (PvPI) — India's adverse drug reaction monitoring system.
• Non-Communicable Diseases (NCD) burden in India — hypertension prevalence context for hydrochlorothiazide use.

10. Common Errors / Trap Areas

• Confusing IARC (WHO's cancer research agency) with WHO itself — IARC is a specialised, semi-autonomous agency, not a WHO department directly issuing treatment guidelines.
• Mistaking Group 1 (hazard identification) for a statement of high absolute risk — aspirants often equate classification group with likelihood/severity.
• Confusing the three drugs' indications: hydrochlorothiazide (hypertension) vs. voriconazole (antifungal) vs. tacrolimus (immunosuppressant) — easy to swap in MCQs.
• Assuming the classification recommends discontinuation — experts explicitly caution against this without medical consultation [3].
• Misdating the finding to 2026 without noting the preliminary November 2024 Lancet Oncology publication predates the full Volume 137 monograph.